Abcam, ab257532, Human MBD1 knockout HeLa cell lysate

Size: 1Kit
MBD1 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-MBD1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Methyl-CpG binding domain protein 1 (MBD1) also known as CXXC-type and BYE1 domain containing 1 recognizes and binds to methylated CpG sites in the DNA. This protein has a molecular weight of approximately 70 kDa. MBD1 is expressed widely in human tissues with higher levels detectable in the brain particularly the cerebral cortex. It acts within the nucleus where it functions as an important participant in the regulation of gene expression through DNA methylation.
Biological function summary
MBD1 influences the repression or activation of genomic transcription. It binds to methylated DNA and interacts with other proteins including methyl CpG binding proteins to form transcriptional repression complexes. This activity plays a role in gene silencing and modulation. MBD1 ensures proper interpretation of epigenetic marks therefore sustaining cellular identity and lineage commitment. In some cells MBD1 also engages with chromatin remodeling complexes to influence chromatin structure.
Pathways
MBD1 plays a significant role in the epigenetic and transcription regulation pathways. It is directly involved in DNA methylation processes interacting with histone deacetylases such as HDAC1 and other chromatin-modifying proteins. The pathway provides an important mechanism for long-term transcriptional silencing affecting developmental processes and cellular differentiation through methylation-dependent transcriptional regulation. MBD1 shares pathway interactions with proteins like MeCP2 highlighting interconnected roles in maintaining DNA methylation landscapes.
MBD1 has links to neurological disorders and cancer. It shows associations with Rett syndrome a neurodevelopmental disorder through its interaction with other methyl CpG binding proteins. Mutations or dysregulation in MBD1’s function can disrupt normal methylation patterns contributing to gene expression changes seen in disease states. In cancer aberrant MBD1 expression may lead to inappropriate gene silencing impacting tumor suppressor genes. Many cancers including glioblastoma exhibit altered MBD1 expression levels implicating its role in tumorigenesis.